Bioequivalence and Bioavailability Forum

Hi Helmut,

❝ ❝ B) Capture day 1 PK from time 0 to end of dosing interval, repeat dosing for x # of days (base on dosing interval) to hit SS. On last day of dosing capture time 0 - x (x = whatever hrs needed to fully capture the elimination phase + half-life).

❝

❝ To characterize the PK of a new drug by PK modeling you would always go with this approach and sample as long as possible. Funky things may happen in nonlinear PK (auto-induction / -inhibition, capacity-limited elimination, …)

I don't think the proposed scheme is good enough for modelling such difficult things. There are no Ctau's planned. Moreover, I would mix the A and B for that purpose.

And sorry for a broken link, I cannot carve in my mind that tags for years